Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2401–2424 of 2,740 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Gastrointestinal Carcinoma Clear all
Completed No phase listed Observational

Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients

NCT02374411
View directory record Official record
Conditions
Pseudomyxoma Peritonei, Appendiceal Neoplasms, Pancreatic Neoplasms, Neoplasm Metastasis, Adenocarcinoma, Sarcoma, Uterine Neoplasms
Interventions
Not listed
Lead sponsor
Edward Hospital
Other
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Naperville, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Nov 15, 2026, 2:33 AM EST
Completed Phase 2 Interventional Results available

Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery

NCT00049322
View directory record Official record
Conditions
Liver Cancer
Interventions
bevacizumab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Nov 15, 2026, 2:33 AM EST
Completed Phase 2 Interventional Results available

Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma

NCT00183794
View directory record Official record
Conditions
Ovarian Carcinoma, Peritoneal Neoplasms
Interventions
Docetaxel and Gemcitabine
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Nov 15, 2026, 2:33 AM EST
Completed Phase 2 Interventional

Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas

NCT00215995
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Cisplatin, Irinotecan, ZD 1839
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 13, 2012 · Synced Nov 15, 2026, 2:33 AM EST
Terminated Phase 1 Interventional

A Study of PY314 in Subjects With Advanced Solid Tumors

NCT04691375
View directory record Official record
Conditions
Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer, Colorectal Cancer, Lung Adenocarcinoma, Renal Cell Carcinoma, Triple Negative Breast Cancer, Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer, Ovarian Cancer
Interventions
PY314, Combination Therapy: PY314 + Pembrolizumab
Drug
Lead sponsor
Ikena Oncology
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
23
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Nov 15, 2026, 2:33 AM EST
Completed Phase 2 Interventional Results available

Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma

NCT04798781
View directory record Official record
Conditions
Gastric Cancer, Hepatocellular Carcinoma
Interventions
Telatinib, Keytruda
Drug
Lead sponsor
Andrew Hendifar, MD
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Beverly Hills, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Nov 15, 2026, 2:33 AM EST
Withdrawn Phase 3 Interventional

Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC)

NCT01318200
View directory record Official record
Conditions
Recurrent Hepatocellular Carcinoma
Interventions
Transarterial Chemoembolization, CyberKnife SBRT
Procedure · Radiation
Lead sponsor
Accuray Incorporated
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2012 · Synced Nov 15, 2026, 2:33 AM EST
Active, not recruiting Phase 3 Interventional

A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

NCT03778957
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Durvalumab, Bevacizumab, Placebo, Transarterial Chemoembolization (TACE)
Drug · Other · Procedure
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 110 Years
Enrollment
724 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
24
States / cities
Costa Mesa, California • La Jolla, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Nov 15, 2026, 2:33 AM EST
Completed Phase 1 Interventional

An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors

NCT03735628
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatocellular Carcinoma (HCC)
Interventions
Copanlisib, Nivolumab
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Beverly Hills, California • Los Angeles, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Nov 15, 2026, 2:33 AM EST
Completed Not applicable Interventional Results available

Clinical Outcomes for Offering Genetic Testing in a Tiered Approach

NCT04902144
View directory record Official record
Conditions
Breast Carcinoma, Colon Carcinoma, Malignant Solid Neoplasm, Ovarian Carcinoma, Pancreatic Carcinoma, Prostate Carcinoma
Interventions
Electronic Health Record Review, Questionnaire Administration, Behavioral Intervention
Other · Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
19 Years to 90 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sequim, Washington
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Nov 15, 2026, 2:33 AM EST
Withdrawn No phase listed Observational

A Study to Estimate Overall Survival in Patients Receiving Best Supportive Care for Treatment-Resistant, Metastatic Colorectal Carcinoma

NCT03096899
View directory record Official record
Conditions
Metastatic Colorectal Carcinoma
Interventions
Observational
Other
Lead sponsor
The Rogosin Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Nov 15, 2026, 2:33 AM EST
Completed Phase 2 Interventional Results available

Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)

NCT01327612
View directory record Official record
Conditions
Advanced Solid Tumors, Carcinoid, Colorectal Cancer, Locally Advanced, Lymphoma, Metastatic Cancer, Non-Small Cell Lung Cancer, Sarcoma, Solid Tumors
Interventions
Modified FOLFOX6, Conatumumab, Ganitumab, Bevacizumab
Drug · Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
10
States / cities
Duarte, California • La Jolla, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Nov 15, 2026, 2:33 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

NCT06521567
View directory record Official record
Conditions
Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma, Glioblastoma Multiforme (GBM), Diffuse Intrinsic Pontine Glioma (DIPG), Ependymoma, Osteosarcoma, Hepatic Tumors, Hepatoblastoma, Hepatocellular Carcinoma (HCC), Fibrolamellar Carcinoma, Rhabdomyosarcoma
Interventions
Cobolimab, Dostarlimab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
0 Years to 21 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Iowa City, Iowa • Hackensack, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Nov 15, 2026, 2:33 AM EST
Active, not recruiting Phase 2 Interventional Results available

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

NCT02867592
View directory record Official record
Conditions
Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma, Central Nervous System Neoplasm, Childhood Clear Cell Sarcoma of Soft Tissue, Clear Cell Sarcoma of Soft Tissue, Ewing Sarcoma, Hepatoblastoma, Hepatocellular Carcinoma, Osteosarcoma, Recurrent Adrenal Cortical Carcinoma, Recurrent Alveolar Soft Part Sarcoma, Recurrent Clear Cell Sarcoma of Soft Tissue, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Hepatocellular Carcinoma, Recurrent Kidney Wilms Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma, Recurrent Primary Malignant Central Nervous System Neoplasm, Recurrent Renal Cell Carcinoma, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Thyroid Gland Medullary Carcinoma, Refractory Adrenal Cortical Carcinoma, Refractory Alveolar Soft Part Sarcoma, Refractory Clear Cell Sarcoma of Soft Tissue, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Hepatocellular Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Osteosarcoma, Refractory Primary Central Nervous System Neoplasm, Refractory Primary Malignant Central Nervous System Neoplasm, Refractory Renal Cell Carcinoma, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory Thyroid Gland Medullary Carcinoma, Refractory Wilms Tumor, Renal Cell Carcinoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Solid Neoplasm, Thyroid Gland Medullary Carcinoma, Wilms Tumor
Interventions
Cabozantinib, Cabozantinib S-malate, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 30 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
142
States / cities
Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 104 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2026 · Synced Nov 15, 2026, 2:33 AM EST
Completed Phase 1 Interventional

Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity

NCT00825201
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cavity Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
paclitaxel albumin-stabilized nanoparticle formulation, liquid chromatography, mass spectrometry, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
19 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
2
States / cities
Duarte, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 15, 2026, 2:33 AM EST
Completed No phase listed Observational

TheraSphere HUD For Treatment of Unresectable Hepatocellular Carcinoma (HCC)

NCT00683631
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
TheraSphere HUD
Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2021
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Nov 15, 2026, 2:33 AM EST
Recruiting Phase 2 Interventional

The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)

NCT06789757
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Memantine Hydrochloride, Bevacizumab, Atezolizumab
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Fairfax, Virginia • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 15, 2026, 2:33 AM EST
Terminated Not applicable Interventional

Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers

NCT04077372
View directory record Official record
Conditions
Gastrointestinal Cancer, Colorectal Cancer, Pancreatic Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Cholangiocarcinoma, Hepatocellular Carcinoma, Neuroendocrine Tumors, GIST, Malignant
Interventions
Serious Illness Conversation Guide (SICG), Quality of Life (QOL) survey
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2023 · Synced Nov 15, 2026, 2:33 AM EST
Completed No phase listed Observational

Clinical Validation of a Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer (VERIFI)

NCT06947395
View directory record Official record
Conditions
Cancer of the Pancreas, Pancreatic Cancer, Pancreas Neoplasms, Pancreatic Carcinoma Stage I, Pancreatic Carcinoma Stage II
Interventions
PancreaSure
Diagnostic Test
Lead sponsor
Immunovia, Inc.
Industry
Eligibility
45 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
6
States / cities
Scottsdale, Arizona • New York, New York • Pittsburgh, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Nov 15, 2026, 2:33 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers

NCT02349412
View directory record Official record
Conditions
Liver Cancer, Anxiety Disorder, Depression, Small Cell Lung Cancer, Extrahepatic Bile Duct Cancer, Malignant Mesothelioma, Pancreatic Cancer, Esophageal Cancer, Gastric Cancer, Non-small Cell Lung Cancer
Interventions
Early palliative care
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
23
States / cities
La Jolla, California • Honolulu, Hawaii • Chicago, Illinois + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Nov 15, 2026, 2:33 AM EST
Terminated Phase 1 Interventional

A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)

NCT02576665
View directory record Official record
Conditions
Colorectal Cancer, Triple Negative Breast Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, Head and Neck Cancer, Ovarian Cancer, Lymphoma, Sarcoma, Bladder Cancer, Melanoma, IDH1 Mutated Solid Tumors, IDH1 Mutated or MGMT Methylated Recurrent HGG (Not Recruiting)
Interventions
Toca 511, Toca FC
Biological · Drug
Lead sponsor
Tocagen Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Denver, Colorado • Miami, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Nov 15, 2026, 2:33 AM EST
Completed Phase 1 Interventional

Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors

NCT00667641
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bortezomib, paclitaxel
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 10, 2011 · Synced Nov 15, 2026, 2:33 AM EST
Active, not recruiting Phase 1 Interventional

A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

NCT03845166
View directory record Official record
Conditions
Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer, Colorectal Cancer
Interventions
XL092, Atezolizumab, Avelumab
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
40
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Nov 15, 2026, 2:33 AM EST
Completed Phase 1 Interventional

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors

NCT05795595
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma, Pancreatic Adenocarcinoma, Malignant Pleural Mesothelioma
Interventions
CTX131
Biological
Lead sponsor
CRISPR Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Duarte, California • Chicago, Illinois • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 15, 2026, 2:33 AM EST